Predicting in vivo cardiovascular properties of β‐blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses
Open Access
- 24 August 2011
- journal article
- research article
- Published by Wiley in The FASEB Journal
- Vol. 25 (12) , 4486-4497
Abstract
β‐Adrenoceptor antagonists differ in their degree of partial agonism. In vitro assays have provided information on ligand affinity, selectivity, and intrinsic efficacy. However, the extent to which these properties are manifest in vivo is less clear. Conscious freely moving rats, instrumented for measurement of heart rate (β1; HR) and hindquarters vascular conductance (β2; HVC) were used to measure receptor selectivity and ligand efficacy in vivo . CGP 20712A caused a dose‐dependent decrease in basal HR ( P n =6), whereas other β‐blockers caused significant reductions (all at 2 mg/kg i.v.). The agonist effects of xamoterol and ZD 7114 were equivalent to that of the highest dose of isoprenaline. Bucindolol, however, significantly antagonized the response to the highest doses isoprenaline. An excellent correlation was obtained between in vivo and in vitro measures of β1‐adrenoceptor efficacy ( R 2 =0.93; P in vivo cardiovascular properties of β‐blockers from cellular assays: a quantitative comparison of cellular and cardiovascular pharmacological responses. FASEB J. 25, 4486–4497 (2011). www.fasebj.orgKeywords
This publication has 59 references indexed in Scilit:
- Evolution of β-blockers: from anti-anginal drugs to ligand-directed signallingTrends in Pharmacological Sciences, 2011
- The selectivity of β‐adrenoceptor agonists at human β1‐, β2‐ and β3‐adrenoceptorsBritish Journal of Pharmacology, 2010
- Nebivolol in chronic heart failure: current evidence and future perspectivesExpert Opinion on Pharmacotherapy, 2010
- Are we misunderstanding beta-blockersInternational Journal of Cardiology, 2007
- Distinct Signaling Profiles of β1 and β2 Adrenergic Receptor Ligands toward Adenylyl Cyclase and Mitogen-Activated Protein Kinase Reveals the Pluridimensionality of EfficacyMolecular Pharmacology, 2006
- The selectivity of β‐adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptorsBritish Journal of Pharmacology, 2005
- Optimising the Use of ??-Adrenoceptor Antagonists in Coronary Artery DiseaseDrugs, 2005
- The prevention of migraine: a critical review with special emphasis on β‐adrenoceptor blockersBritish Journal of Clinical Pharmacology, 2001
- Use of β-Adrenoceptor Blocking Drugs in HyperthyroidismDrugs, 1984
- Effect of chronic beta-adrenergic receptor blockade in congestive cardiomyopathy.Heart, 1975